BACKGROUND: Efavirenz has been associated with neuropsychiatric disorders, but little is known about depression and quality of life in sub-Saharan Africa, where nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are still the first-line treatment recommended by the World Heath Organization (WHO) and are widely prescribed. METHODS: In a cross-sectional study, we evaluated quality of life and depression among Senegalese patients receiving efavirenz- or protease inhibitor (PI)-based regimens. Two hundred consecutive patients who had been taking highly active antiretroviral therapy (HAART) for more than 6 months were asked to complete a questionnaire. RESULTS: According to the Center for Epidemiologic Studies Depression Scale (CES-D), 18% had depression (19% for patients on a PI-based regimen and 17% for patients on efavirenz-based treatment). Fifty-nine per cent of the patients reported no health problems in the past 4 weeks. A quarter of patients had sleep disorders. Moderate or slight adverse events were reported by 28.5% of patients. CONCLUSIONS: Quality of life and depression scores remained good in both study groups. However, quality of life and depression should be monitored in follow-up of HIV-infected patients in sub-Saharan Africa.
BACKGROUND:Efavirenz has been associated with neuropsychiatric disorders, but little is known about depression and quality of life in sub-Saharan Africa, where nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are still the first-line treatment recommended by the World Heath Organization (WHO) and are widely prescribed. METHODS: In a cross-sectional study, we evaluated quality of life and depression among Senegalese patients receiving efavirenz- or protease inhibitor (PI)-based regimens. Two hundred consecutive patients who had been taking highly active antiretroviral therapy (HAART) for more than 6 months were asked to complete a questionnaire. RESULTS: According to the Center for Epidemiologic Studies Depression Scale (CES-D), 18% had depression (19% for patients on a PI-based regimen and 17% for patients on efavirenz-based treatment). Fifty-nine per cent of the patients reported no health problems in the past 4 weeks. A quarter of patients had sleep disorders. Moderate or slight adverse events were reported by 28.5% of patients. CONCLUSIONS: Quality of life and depression scores remained good in both study groups. However, quality of life and depression should be monitored in follow-up of HIV-infectedpatients in sub-Saharan Africa.
Authors: Jane M Simoni; Steven A Safren; Lisa E Manhart; Karen Lyda; Cynthia I Grossman; Deepa Rao; Matthew J Mimiaga; Frank Y Wong; Sheryl L Catz; Michael B Blank; Ralph DiClemente; Ira B Wilson Journal: AIDS Behav Date: 2011-02
Authors: Jonathan L Chang; Alexander C Tsai; Nicholas Musinguzi; Jessica E Haberer; Yap Boum; Conrad Muzoora; Mwebesa Bwana; Jeffrey N Martin; Peter W Hunt; David R Bangsberg; Mark J Siedner Journal: Ann Intern Med Date: 2018-06-26 Impact factor: 25.391
Authors: Matthew P Fox; Kelly McCoy; Bruce A Larson; Sydney Rosen; Margaret Bii; Carolyne Sigei; Douglas Shaffer; Fred Sawe; Monique Wasunna; Jonathon L Simon Journal: AIDS Care Date: 2010-02
Authors: John Farley; Erin Miller; Andrew Zamani; Vicki Tepper; Chester Morris; Modupe Oyegunle; Maria Lin; Manhattan Charurat; William Blattner Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2010 Jul-Aug
Authors: Patrick O Monahan; Enbal Shacham; Michael Reece; Kurt Kroenke; Willis Owino Ong'or; Otieno Omollo; Violet Naanyu Yebei; Claris Ojwang Journal: J Gen Intern Med Date: 2008-11-20 Impact factor: 5.128
Authors: Etheldreda Nakimuli-Mpungu; Ramin Mojtabai; Pierre K Alexandre; Elly Katabira; Seggane Musisi; Jean B Nachega; Judith K Bass Journal: HIV AIDS (Auckl) Date: 2012-04-12